Evidence map›Paper›PMID 32922200›Full record

ArticleInternational journal of medical sciences2020

Conjugation of TLR7 Agonist Combined with Demethylation Treatment Improves Whole-Cell Tumor Vaccine Potency in Acute Myeloid Leukemia.

Guocheng Zhong, Guangyi Jin, Wei Zeng, Changhua Yu, Yan Li, Ji Zhou, Li Zhang, Li Yu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of medical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Therapeutic applications of toll-like receptors (TLRs) agonists in AML.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Guocheng ZhongDepartment of Hematology and BMT center, the first Medical Center, Chinese PLA General Hospital. Beijing 100853, China.
Guangyi JinCarson International Cancer Center, Department of Medicine, Shenzhen University, Shenzhen 518037, China.
Wei ZengDepartment of Hematology and Oncology, Shenzhen University General Hospital, Shenzhen 518055, China.
Changhua YuDepartment of Hematology and Oncology, Shenzhen University General Hospital, Shenzhen 518055, China.
Yan LiDepartment of Hematology and BMT center, the first Medical Center, Chinese PLA General Hospital. Beijing 100853, China.
Ji ZhouCarson International Cancer Center, Department of Medicine, Shenzhen University, Shenzhen 518037, China.
Li ZhangCarson International Cancer Center, Department of Medicine, Shenzhen University, Shenzhen 518037, China.
Li YuDepartment of Hematology and BMT center, the first Medical Center, Chinese PLA General Hospital. Beijing 100853, China.
Shenzhen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAntigens, NeoplasmCancer VaccinesCell Line, TumorDecitabineDendritic CellsDNA MethylationHumansLeukemia, Myeloid, AcuteMicePrimary Cell CultureT-LymphocytesToll-Like Receptor 7Vaccine PotencyXenograft Model Antitumor AssaysAntigens, NeoplasmCancer VaccinesDecitabineTLR7 protein, humanToll-Like Receptor 7AMLSZU-106TLR7vaccine.

Identifiers

PMID32922200
PMCPMC7484644
OpenAlexW3083876283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.